Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Elizabeth A. Brem, Kevin Shieh, Dennis Juarez, Roberta Buono, Susan O’Brien, David A. Fruman
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
10.1038/nm.3048 · 2013
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
10.1182/blood.2020004856 · 2020
First-line venetoclax combinations in chronic lymphocytic leukemia
10.1056/nejmoa2213093 · 2023
Targeting the mevalonate pathway in cancer
10.1016/j.trecan.2020.11.008 · 2021
Statins enhance efficacy of venetoclax in blood cancers
10.1126/scitranslmed.aaq1240 · 2018
Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors
10.1158/2767-9764.crc-23-0350 · 2023
Report of the relapsed/refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)
10.1016/j.leukres.2018.01.021 · 2018
The poor design of clinical trials of statins in oncology may explain their failure - lessons for drug repurposing
10.1016/j.ctrv.2018.06.010 · 2018
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1182/blood-2007-06-093906 · 2008
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017
Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study
10.1200/jco.2014.60.0890 · 2015
Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx)
10.1182/blood-2020-136109 · 2020
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
10.1515/hsz-2016-0107 · 2016
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
10.1186/s13045-023-01417-5 · 2023
The mevalonate pathway is a therapeutic target in TP53 mutant acute myeloid leukemia
10.1182/blood-2023-185059 · 2023
No additional external references are available.